EUVIMEDEUVIMED entdecken
EditorialKommentarOpen Access

Durvalumab and bevacizumab plus transarterial chemoembolization in unresectable hepatocellular carcinoma: a new paradigm?

Maen Abdelrahim, Abdullah Esmail, Bandar Al-Judaibi

Translational Gastroenterology and Hepatology · 2026-01 · 11 · 1-1

DOI: 10.21037/tgh-25-34 ↗

Kurz gefasst

Editorial in der Zeitschrift Translational Gastroenterology and Hepatology, 2026-01. Verfasst von Maen Abdelrahim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Section of GI Oncology, Houston Methodist Cancer Center, Houston Methodist Hospital, Houston, TX, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Hepatocellular carcinoma (HCC)Milan criteriabridging therapycheckpoint inhibitorsliver transplant

Autor:innen und Institutionen

  • Section of GI Oncology, Houston Methodist Cancer Center, Houston Methodist Hospital, Houston, TX, USA.
  • Department of Gastroenterology & Hepatology, Faculty of Medicine, The University of Jordan, Amman, Jordan.
  • Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Centre, Riyadh, Kingdom of Saudi Arabia.

Zitieren

APA

Abdelrahim, M., Esmail, A., & Al-Judaibi, B. (2026). Durvalumab and bevacizumab plus transarterial chemoembolization in unresectable hepatocellular carcinoma: a new paradigm?. Translational Gastroenterology and Hepatology, 11, 1-1. https://doi.org/10.21037/tgh-25-34

Vancouver

Abdelrahim M, Esmail A, Al-Judaibi B. Durvalumab and bevacizumab plus transarterial chemoembolization in unresectable hepatocellular carcinoma: a new paradigm?. Translational Gastroenterology and Hepatology. 2026;11:1-1. doi:10.21037/tgh-25-34

BibTeX
@article{Abdelrahim2026,
  author = {Abdelrahim, Maen and Esmail, Abdullah and Al-Judaibi, Bandar},
  title = {Durvalumab and bevacizumab plus transarterial chemoembolization in unresectable hepatocellular carcinoma: a new paradigm?},
  journal = {Translational Gastroenterology and Hepatology},
  year = {2026},
  volume = {11},
  pages = {1--1},
  doi = {10.21037/tgh-25-34}
}
Kostenlos starten →